



Drug Monograph

Drug/Drug **Intraventricular Electrolytes /Biologic**

Class:

Prepared for: MO HealthNet

Prepared by: Conduent

New Criteria

Revision of Existing Criteria

Executive Summary

Purpose:	The purpose of this monograph is to provide a review of new therapy to determine whether the reviewed drug should be made available on an open access basis to prescribers, require a clinical edit or require prior authorization for use.
Dosage Forms:	Intraventricular Electrolytes are included with the Brineura [®] Carton. It is available in a 5 ml vial for intraventricular infusion only.
Manufacturer:	BioMarin Pharmaceutical Inc., Novato, CA 94949.
Indications:	Intraventricular Electrolytes are infused following Brineura [®] . They are used to flush the infusion line, port needle, and intraventricular access device in order to fully administer Brineura [®] and to maintain patency of the intraventricular access device.
Costs:	Pricing information not available at this time.
Summary of Findings:	MO HealthNet Division recommends Open Access status for this product.
Status Recommendation:	<input type="checkbox"/> Prior Authorization (PA) Required <input checked="" type="checkbox"/> Open Access <input type="checkbox"/> Fiscal Edit <input type="checkbox"/> PDL
Type of PA Criteria:	<input type="checkbox"/> Increased Risk of ADE <input type="checkbox"/> Under Solicitation <input type="checkbox"/> Appropriate Indications <input checked="" type="checkbox"/> No PA Required

Prepared By: Luke Boehmer PharmD

Date: November 17, 2017